anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Nigeria is one of the developing countries with a major burden of non-communicable diseases (NCDs) without a disease self-management program in its healthcare system. Thus, this study was aimed to assess the baseline self-efficacy levels of Nigerian patients with chronic NCDs at tertiary level hospitals. This is a cross sectional study of 286 NCD patients attending tertiary level clinics from 26 July to 27 October 2023. Patients were interviewed on a 10 Self-Efficacy to Manage Chronic Disease (SEMCD) item scales that were considered suitable for the Nigerian population. The 10 SEMCD questions covered: (i) Exercise regularly scale, (ii) Help from community, family and friends scale, (iii) Communication with Physician scale, (iv) Manage disease scale and (v) Manage symptom self-efficacy domains. Data were analyzed both descriptively and statistically using Student's t-tests and Chi-square tests as appropriate. The results showed that more female (59.4%) than males (40.6%) attended clinics during the study, and the mean age of the patients did not differ between gender (P > .05). About 40% of all the patients manage their NCDs with medications alone, a trend that is similar in male and female patients (P > .05). While all the patients had a relatively lower self-efficacy scores under regular exercise scale (52%-55%) and manage disease symptoms scale (53%-55%), they tended toward higher self-efficacy scores under getting assistance from community, family, and friends (79%-80%) and communication with attending physicians (81%-85%). It is concluded that Nigeria literate NCD patients registered at tertiary level institution routine clinics are less than optimal in disease self-management care. We recommend that this study population will benefit from introduction and implementation of disease self-management program in the healthcare system.
PURPOSE:To provide an anticariogenic substance composed of glycyrrhizin extracted from KANZO (root of Glycyrrhiza glabra), suppressing the formation of glucan by cariogenic bacteria, surely inhibiting the formation of bacterial plaque and having excellent effect to prevent dental caries. CONSTITUTION:An anticariogenic substance having excellent effect to inhibit the formation of bacterial plaque can be produced by compounding preferably >=1mM of glycyrrhizin which is a kind of glucoside extracted from the root of KANZO as an essential component and preferably further compounding gymnemic acid. The anticariogenic substance surely prevents the formation of dental caries by the anticariogenic effect of glycyrrhizin even by taking conventional foods and drinks containing sucrose and starch. Gymnemic acid suppresses with sweet taste of glycyrrhizin and refreshes the oral cavity. Glycyrrhizin is a known agent having steroidal action, anti-inflammatory action, antiarteriosclerotic action, etc., and gymnemic acid is a known agent for suppressing sweet taste. Both are harmless to human body.
PCT No. PCT/AU95/00707 Sec. 371 Date Jun. 17, 1997 Sec. 102(e) Date Jun. 17, 1997 PCT Filed Oct. 25, 1995 PCT Pub. No. WO96/12466 PCT Pub. Date May 2, 1996A controlled release container includes an outer shell and a separately produced core that comprises at least one bioactive molecule. At least a portion of the outer shell comprises a biodegradable polymeric material that has a predetermined rate of degradation. The outer shell preferably is non-porous and provides a predetermined delay of at least two days from administration of the capsule before release of the active ingredient.
A research MRI exam that uses the signal from a finger pulse oximeter to synchronize the MRI scan to the subjects heart beat will be acquired. The Gadavist contrast injection will be used during this MRI examination to provide images of cerebral blood flow which will serve as reference standard to identify regions of the brain compromised by cerebral vascular disease. The experimental MRI scan in this case is intended to measure the utilization of oxygen by the brain which is believed to be a predictor of future stroke. All arm 1 procedures will be performed either at Northwestern or University of Chicago.
This invention relates to an improved polyvinylidene fluoride-based composition useful for forming a flexible, tack-free, nonflammable, substantially fluid resistant barrier film with substantially improved durability and skin-adhesion properties. The composition providing a long-lasting protective barrier film capable of disinfecting the skin surface of normally present microorganisms upon initial application, and the film imparting continuous and prolonged antimicrobial agent. The barrier film is further capable of remaining substantially adherent to the skin surface after prolonged exposure to biological fluids. A kit and methods of use for the composition are disclosed. The figure illustrates the moisture vapor transmission rate (MTVR) for the present invention. The MTVR of the present invention containing both chlorhexidine acetate (CHA) and silver sulfadiazine (AgSD), chlorhexidine alone, and with no antimicrobial agent present is compared against BLISTERFILM~TM hydrocolloid wound dressing and Saran(R) food wrap. The percent of water loss is plotted versus time in days. The data illustrating the present invention is breathable, thereby providing patient comfort and promotion of wound healing. See Test #3 for details.
Hepatocellular carcinoma (HCC) is caused by various factors including toxic substances and xenobiotics. Numerous treatment strategies are used to address toxicity to the liver and HCC, yet their adverse effects are drawbacks. This study aimed to assess the effect of DEN/CCl4 on morphological changes in the liver, body weight, tumor incidence, and hematological tumor incidence, hematological parameters, hepatic markers, and histopathological analysis in mice following a preventive measure by using β-caryophyllene (BCP). Adult Balb/c mice were administered a single dose of DEN 1-mg/kg body weight and 0.2-mL CCl4/kg body weight intraperitoneal twice a week (i.p.) for 22 weeks. BCP was treated in one group of mice at 30-mg/kg body weight, intraperitoneal, for 7 weeks. BCP alone was treated in one group of mice at 300-mg/kg body weight intraperitoneal for 22 weeks. DEN/CCl4 caused a reduction in mice's body weight, which was significantly attenuated by BCP administration. BCP supplementation attenuated the tumor incidence DEN/CCl4 (100%) to about 25%. DEN/CCl4 caused alterations in the hematological parameters, serum total protein albumin globulin, A/G ratio, liver function markers (AST, ALT, ALP, GGT, ACP, and bilirubin), and lipid profile markers that were significantly reinstated by BCP administration. Oxidative stress markers (MDA, SOD, CAT, NO, LDH, and GST) were reduced by DEN/CCl4, which were significantly increased in BCP-treated groups. The liver histopathology alterations caused by DEN/CCl4 were amended considerably by BCP treatment. Immunohistochemical studies suggest that AFP, caspase-3, and COX-2 were chronically overexpressed in DEN/CCl4-exposed mice, notably attenuated by BCP administration. BCP suppressed tumor incidence by downregulating inflammation and inducing caspase-3-mediated apoptosis. Conclusively, BCP appears to be a potent natural supplement capable of repressing liver inflammation and carcinoma through the mitigation of oxidative stress and inflammation pathways.
Telerehabilitation-based physiotherapy program + telerehabilitation-based motor imagery training Telerehabilitation-based physiotherapy program; Eight (8) weeks, three (3) sessions per week, 40 minutes, using an image-based rehabilitation system, by connecting volunteers with a physiotherapist online in their home environment. Telerehabilitation-based motor imagery training will only be applied to the treatment group by the same physiotherapist for 15-20 minutes in addition to the physiotherapy training, three (3) sessions per week for eight (8) weeks.
The present invention relates to a method for producing a povidone iodine complex. The background technology for the present invention is the method for producing a povidone iodine complex. The present invention aims to reduce the production processes. The present invention relates to a method for producing a mixture of povidone and iodine in a vacuum state at the temperature of 42 to 72°C. The present invention may have the same or increased disinfection effect even when povidone potassium is produced with reduced production processes. The present invention relates to a method for producing the povidone potassium by subjecting the mixture of povidone and iodine to the vacuum state at the temperature of 42 to 72°C.
The invention relates to a biological product for animal and the preparation method, especially relates to a kind of shigellosis inactivated emulsion vaccine for chicken and the preparation method. The method comprises breeding chicken shigellosis, adjusting concentration, deactivating, and adding adjuvant according to a proper ratio. The chicken shigellosis amount in vaccine is 500 million-750milliom / ml. The emulsion vaccine and shigellosis deactivated alumina gel vaccine chicken are used together for chicken immunization to prevent shigellosis infection in chicken. It is tested that the cell immunization and body liquid immunization for immunized animal are increased distinctively, the immunization protection rate is above 85.1-100%. The vaccine is characterized by stable property, easy store, non-toxic, non-pollution, fast and strong immunization effect, high protective rate and simple operation. The invention belongs to livestock cultivation field, and has great importance for preventing and controlling shigellosis in chicken and cross-infection in human and chicken.
PURPOSE: Self-stigma occurs when a person internalizes and applies stereotypes, prejudice, and discrimination to themselves. For adults who stutter, self-stigma is linked to negative outcomes and reduced quality of life. The development of self-stigma in people who stutter is not well understood. The aim of this study is to evaluate stuttering self-stigma in school-age children and adolescents and explore potential relationships to stuttering's overall adverse impact.
METHOD: One hundred one children and adolescents who stutter, aged 10-18 years, completed the Overall Assessment of the Speaker's Experience of Stuttering (OASES), a measure of adverse impact related to stuttering, and the Childhood Self-Stigma of Stuttering Scale (Child 4S), our novel adapted version of the Self-Stigma of Stuttering Scale (4S) created for this study. The Child 4S comprises three subscales measuring three stages of self-stigma: Awareness, Agreement, and Application. Each stage was evaluated for relationships with child age and the adverse impact of stuttering.
RESULTS: We found a range of self-stigma scores among children and adolescents who stutter. Child age did not correlate with Awareness and Agreement; however, older children and adolescents reported greater Application. All stages of self-stigma strongly predicted adverse impact as measured by the OASES, and latter stages of the model were stronger predictors than earlier stages.
CONCLUSIONS: Children as young as 10 years old may experience stuttering self-stigma, and the application of self-stigma increases in adolescence, a critical period in the development of personal identity. Importantly, all stages of self-stigma predicted adverse impact related to stuttering, with latter stages being stronger predictors than earlier ones consistent with the progressive model of self-stigma being tested. The findings highlight the need for targeted, early intervention to mitigate downstream effects of stuttering self-stigma.
SUPPLEMENTAL MATERIAL: https://doi.org/10.23641/asha.26352556.
National and international guidelines, hospital protocols, the anesthesiologist's experience, and the patient's decision play a role in selecting the technique used for postoperative analgesia after cesarean section. The quality of recovery score experienced following elective cesarean section in a total of 180 patients over one year (December 31, 2021-2022) who applied subarachnoid morphine, lateral TAP block, posterior-TAP block, QL block, ESP block, and TFD block (30 patients for each technique) will be evaluated with the ObsQoR-10 questionnaire 24 hours after delivery. The regional anesthesia techniques information applied to the patients will be obtained from the patient file. Researchers will not perform any interventional procedure, and any randomization will not be applied. After the data collection process for the study is completed, ObsQoR-10 will be compared statistically. The secondary aims of this study are to compare the cases in terms of postoperative analgesia and antiemetic requirements, first food intake and standing up without support, and patient satisfaction.
The target enrollment number is 30 people with multiple sclerosis who meet inclusion criteria. After informed consent is given, potential subjects will be screened to ensure they meet eligibility criteria. Subjects who meet eligibility criteria will complete baseline assessments and will then be randomized to receive 2 weeks of treatment (Treatment Period 1) with either suvorexant or matching placebo (1:1). The initial dose of suvorexant will be 10 mg at bedtime, with optional titration to 20 mg after 5-7 days. Study drug will be dispensed by an independent research pharmacist, keeping both study staff and the subject blinded. All subjects, whether in placebo or active arm, will receive a wearable sleep monitor to be worn for 7 days at baseline, and during both treatment periods. All subjects will keep 7-day sleep diaries at baseline and during each study period. At the end of Treatment Period 1 (2 weeks), subjects will undergo efficacy assessments with repeated clinical scales. Subjects will then go through a 1-week open-label off-drug washout period. Subjects will then be crossed over into the alternate treatment group, which will once again be double-blinded; those on active treatment (suvorexant) in Treatment Period 1 will be switched to placebo, and those on placebo in Treatment Period 1 will be switched to active treatment. Treatment Period 2 will also be 2 weeks long, and at the end of this, subjects will undergo final assessment with clinical scales.
Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
The toxic dose of misoprostol in humans has not been determined. Cumulative total daily doses of 1600 mcg have been tolerated, with only symptoms of gastrointestinal discomfort being reported.

In animals, the acute toxic effects are diarrhea, gastrointestinal lesions, focal cardiac necrosis, hepatic necrosis, renal tubular necrosis, testicular atrophy, respiratory difficulties, and depression of the central nervous system. Clinical signs that may indicate an overdose are sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, or bradycardia.Symptoms should be treated with supportive therapy. 

It is not known if misoprostol acid is dialyzable. However, because misoprostol is metabolized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for overdosage.
We explore the use of shear wave elastography (SWE) for assessing muscle stiffness and treatment response in cerebral palsy (CP) children by way of a systematic review. SWE offers real-time muscle stiffness measurements, showing significant differences between CP patients and controls. Studies suggest that SWE can be used to follow muscle stiffness post-botulinum toxin treatment, correlating with clinical improvement. However, methodological variations and small sample sizes prevent comparison between different studies. Standardized protocols could enhance SWE's clinical utility. In conclusion, SWE holds promise for CP management, though standardized methodologies and larger studies are needed to validate its efficacy and integration into clinical practice.
PROBLEM TO BE SOLVED: To obtain a plaster having high warming activities and hardly causing a skin irritation by forming a specific substrate layer containing water on a supporter layer comprising a foamed sheet of a synthetic resin and a woven or nonwoven fabric. SOLUTION: This plaster having warm feeling is obtained by forming a hydrophilic substrate layer containing 30-80 wt.% water on a fabric face of a supporter layer obtained by adhering a foamed sheet of a synthetic resin such as polystyrene and polyurethane to a woven or nonwoven fabric. Preferably, the foamed resin sheet has 0.1-10 mm thickness and 0.1-0.3 mm pore diameter, and the pore is preferably a closed cell. The hydrophilic substrate is exemplified by a polyacrylic acid, a gelatin, a casein, a pullulan and a dextran. Formulation of a nonsteroidal antiinflammatory agent such as indomethacin, ketoprofen and felbinac is preferable in view of the effect. The formulation of a blood flow promoter such as vitamin E acetate and a sodium polyethylenesulfonate is preferable in view of increasing effects of a skin temperature.
BACKGROUND: Despite the oral cavity being readily accessible, oral cancer (OC) remains a significant burden. The objective of this study is to develop a DNA ploidy-based cytology test for early detection of high-risk oral lesions.
METHODS: This retrospective study was conducted using 569 oral brushing samples collected from 95 normal and 474 clinically abnormal mucosa with biopsy diagnosis of reactive, low-grade or high-grade precancer or cancers. Brushing cells were processed to characterize DNA ploidy. A two-step DNA ploidy-based algorithm, the DNA ploidy oral cytology (DOC) test, was developed using a training set, and verified in test and validation sets to differentiate high-grade lesions (HGLs) from normal. The prognostic value of the test was evaluated by an independent outcome cohort, including progressed and non-progressing normal, reactive and low-grade lesions. Classification performance was assessed by accuracy, sensitivity, and specificity, while the prognostic value was evaluated by using the Cox proportional hazards analysis on 3-year progression-free survival (PFS).
RESULTS: The developed DOC test exhibited high accuracy for detecting HGLs in the test and validation sets, with a sensitivity of 0.97 and 0.96, respectively. Its application to the Outcome cohort demonstrated significant prognostic value for 3-year PFS (log rank, p < 0.001). Multivariate analysis showed that high-grade pathology was the only variable explaining positive DOC test, not age, smoking, or lesional site.
CONCLUSION: Clinical implementation of the DOC test could provide an effective screening method for detecting HGLs for biopsy and lesions at risk of progression.
This study aimed to estimate the prevalence of malnutrition using clustered anthropometric indicators and to describe the sociodemographic and dietary factors and health conditions that determine malnutrition in elderly Colombians. This was a secondary analysis of the study Health, Well-being and Ageing (SABE) Colombia, 2015. The survey included 23,694 people aged ≥ 60 years. Malnutrition excess was defined by clustering two indicators: body mass index (BMI) and waist circumference; weight deficit was defined by clustering BMI and arm and calf circumferences. The chi-square test was used to associate malnutrition with sociodemographic variables, dietary and health conditions, and to determine the heterogeneity of malnutrition, a latent class analysis was performed. Overweight was 31.9%, whereas underweight, according to BMI and calf circumference, was 7.9%, and increased to 18.8% when arm circumference was also taken into account. Five latent classes of malnutrition were generated - class 1: no overweight and deteriorated health conditions; class 2: no weight deficit and deteriorated health conditions; class 3: no malnutrition and deteriorated health conditions; class 4: overweight and multimorbidity; and class 5: low protein food intake without being underweight or overweight. It is concluded that a high prevalence of malnutrition in older adults exists, with excess rather than deficit. Sociodemographic and dietary factors and health conditions are associated differently with overweight and underweight.
This is a prospective study performed in 20 tertiary medical centers in France. We aim to recruit 150 patients from 2016 to 2020. Patients with a native papilla scheduled for ERCP (endoscopic retrograde cholangiopancreatography) are screened for the study. Patients with a difficult biliary cannulation are included in the study if the guidewire is inserted in the pancreatic duct. At that point, patients are randomized in two arms: early versus delayed DGT. The early arm attempts biliary cannulation using the double-guidewire technique immediately and the delayed arm uses the double-guidewire technique only if 10 more minutes of standard cannulation technique does not allow biliary cannulation. The primary outcome is the biliary cannulation rate success. Secondary outcomes are complications rate and performance of the technique in both arms. Follow-up is 30 days.
Dose escalation trial evaluating OKI-179 given orally on a daily basis. Patients will take OKI-179 orally (PO) on Days 1 - 4, 8 - 11 and 15 - 18 in 21-day cycles (± 3 days), under fasted conditions. The design is a modified 3+3 design to determine the maximum tolerated dose and allows for additional cohorts enrolling subjects with an alternative dosing schedule such as OKI-179 orally (PO) daily on Days 1 - 5, 8 - 12 and 15 - 19 per 21-day cycles or Days 1 - 21 per 21-day cycles to determine the maximum tolerated dose for continuous daily dosing.
ARIXTRA Injection is provided in a single-dose, prefilled syringe affixed with an automatic needle protection system. ARIXTRA is administered by subcutaneous injection. It must not be administered by intramuscular injection. ARIXTRA is intended for use under a physician’s guidance. Patients may self-inject only if their physician determines that it is appropriate and the patients are trained in subcutaneous injection techniques.

Prior to administration, visually inspect ARIXTRA to ensure the solution is clear and free of particulate matter.

To avoid the loss of drug when using the prefilled syringe, do not expel the air bubble from the syringe before the injection. Administration should be made in the fatty tissue, alternating injection sites (e.g., between the left and right anterolateral or the left and right posterolateral abdominal wall).

To administer ARIXTRA: